{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:02:21Z","timestamp":1791414141269,"version":"4.3.3"},"reference-count":10,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,6]]},"abstract":"ABSTRACT<\/jats:title>In this study, susceptibilities were determined for AZD0914, a spiropyrimidinetrione DNA gyrase inhibitor, azithromycin, doxycycline, and levofloxacin againstMycoplasma<\/jats:named-content>andUreaplasma<\/jats:named-content>species. The activity of AZD0914 was comparable to that of levofloxacin and doxycycline againstMycoplasma genitalium<\/jats:named-content>andMycoplasma pneumoniae<\/jats:named-content>. The AZD0914 MIC90<\/jats:sub>againstMycoplasma hominis<\/jats:named-content>was 8-fold greater than that for levofloxacin. The AZD0914 MIC90<\/jats:sub>againstUreaplasma<\/jats:named-content>species was 4-fold less than that for azithromycin and 8-fold less than that for levofloxacin and doxycycline.<\/jats:p>","DOI":"10.1128\/aac.04945-14","type":"journal-article","created":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T09:41:41Z","timestamp":1427881301000},"page":"3627-3629","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":24,"title":["In Vitro<\/i>Antibacterial Activity of AZD0914 against Human Mycoplasmas and Ureaplasmas"],"prefix":"10.1128","volume":"59","author":[{"given":"Ken B.","family":"Waites","sequence":"first","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Crabb","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn B.","family":"Duffy","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Huband","sequence":"additional","affiliation":[{"name":"Infection iMed, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03920-14"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03090-14"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04124-14"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31819e3f7a"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.44.4.1590-1591.2006"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.12.012"},{"key":"e_1_3_2_8_2","volume-title":"Methods for antimicrobial susceptibility testing of human mycoplasmas; approved guideline","author":"Clinical and Laboratory Standards Institute","year":"2011","unstructured":"Clinical and Laboratory Standards Institute. 2011. Methods for antimicrobial susceptibility testing of human mycoplasmas; approved guideline. CLSI document M43-A. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.1.161-165.2003"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1128\/9781555816728.ch59","volume-title":"Manual of clinical microbiology","author":"Waites KB","year":"2011","unstructured":"Waites KB, Taylor-Robinson D. 2011. Mycoplasma and Ureaplasma, p 970\u2013985. In Versalovic J, Carroll K, Funke G, Jorgensen J, Landry M, Warnock D (ed), Manual of clinical microbiology, 10th ed. ASM Press, Washington, DC.","edition":"10"},{"key":"e_1_3_2_11_2","first-page":"289","volume-title":"Mollicutes: molecular biology and pathogenesis","author":"Waites KB","year":"2014","unstructured":"Waites KB, Lysynyansky I, Bebear CM. 2014. Emerging antimicrobial resistance in mycoplasmas of humans and animals, p 289\u2013322. In Browning G, Citti C (ed), Mollicutes: molecular biology and pathogenesis. Caister Academic Press, Norfolk, United Kingdom."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.04945-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.04945-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T03:18:27Z","timestamp":1691551107000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.04945-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1128\/AAC.04945-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.04945-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"2014-12-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-03-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-05-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}